OPTIMAS CAPITAL Ltd Makes New Investment in Pfizer Inc. $PFE

OPTIMAS CAPITAL Ltd purchased a new stake in shares of Pfizer Inc. (NYSE:PFE) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 220,800 shares of the biopharmaceutical company’s stock, valued at approximately $5,626,000. Pfizer accounts for 3.6% of OPTIMAS CAPITAL Ltd’s holdings, making the stock its 12th largest position.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Western Wealth Management LLC boosted its holdings in Pfizer by 11.7% during the 3rd quarter. Western Wealth Management LLC now owns 52,599 shares of the biopharmaceutical company’s stock valued at $1,340,000 after acquiring an additional 5,528 shares during the period. REAP Financial Group LLC boosted its stake in shares of Pfizer by 16.4% during the third quarter. REAP Financial Group LLC now owns 4,948 shares of the biopharmaceutical company’s stock valued at $126,000 after purchasing an additional 697 shares during the period. Blume Capital Management Inc. grew its holdings in shares of Pfizer by 16.5% in the third quarter. Blume Capital Management Inc. now owns 226,621 shares of the biopharmaceutical company’s stock worth $5,774,000 after purchasing an additional 32,088 shares during the last quarter. Allen Holding Inc. NY increased its stake in shares of Pfizer by 49.0% in the third quarter. Allen Holding Inc. NY now owns 1,519,800 shares of the biopharmaceutical company’s stock worth $38,725,000 after buying an additional 500,000 shares during the period. Finally, Cardinal Point Capital Management ULC raised its holdings in Pfizer by 0.7% during the 3rd quarter. Cardinal Point Capital Management ULC now owns 314,272 shares of the biopharmaceutical company’s stock valued at $8,008,000 after buying an additional 2,240 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

PFE has been the topic of a number of recent analyst reports. Citigroup started coverage on shares of Pfizer in a report on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 price target on the stock. Sanford C. Bernstein reissued a “market perform” rating and issued a $30.00 target price on shares of Pfizer in a research note on Friday, October 31st. Zacks Research lowered Pfizer from a “hold” rating to a “strong sell” rating in a research report on Monday, January 26th. Bank of America cut their price objective on Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a research report on Monday, December 15th. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $27.00 target price on shares of Pfizer in a report on Wednesday, February 4th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $28.06.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q4 earnings beat and GLP‑1 topline: Pfizer reported upside on revenue and EPS and released positive Phase 2b results for its lead GLP‑1 candidate (strong placebo‑adjusted weight loss), which helped lift sentiment around a new growth leg. Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters Most
• Positive Sentiment: Management outlines obesity strategy: Pfizer execs signaled the company is “back in the obesity race,” emphasizing development plans and commercialization intent after the encouraging GLP‑1 data. Healthy Returns: Pfizer execs chart out obesity strategy after encouraging drug data
• Positive Sentiment: FDA grants Priority Review for HYMPAVZI sBLA: The agency accepted a supplemental biologics license application to expand HYMPAVZI’s indication to pediatric and inhibitor populations in hemophilia, which could broaden revenue opportunity if approved. FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA
• Positive Sentiment: Mid‑stage obesity candidate complete: Pfizer announced completion of a mid‑stage trial for PF‑07976016, adding to its GLP‑1/obesity development cadence and potential registration pathway. Pfizer Completes Mid-Stage Trial of New Obesity Drug Candidate PF-07976016
• Positive Sentiment: Pipeline & M&A push into oncology and obesity: Analysts and coverage note Pfizer is lining up ~20 pivotal studies after ~ $9B of 2025 M&A, leaning on Seagen assets and AI tools to accelerate R&D — a multi‑year growth story. Pfizer Bets Big on Obesity and Oncology With 2026 Pipeline Push
• Positive Sentiment: Income investor attention: Pfizer appears on recent high‑yield dividend stock lists, which can support demand from yield‑focused investors. 3 High-Yield Dividend Stocks Perfect For Retirees
• Neutral Sentiment: Cost‑savings / affordability program: Pfizer launched a TrumpRx program offering discounts on ~30 medicines — positive for patient access and PR, but the near‑term financial impact is unclear. Pfizer Launches Cost-Savings Program on TrumpRx
• Neutral Sentiment: Analyst views mixed: Coverage notes cautious upside — bullish pipeline/AI drivers balanced by execution risk, time to commercialization, and competitive pressure in GLP‑1s. Pfizer Stock Forecast: Trending Analysts See Cautious Upside
• Negative Sentiment: Early‑stage trial halted: Pfizer paused an early‑stage study for PF‑07258669 in older adults, introducing a specific clinical risk that could require program adjustments. Pfizer Halts Early-Stage Trial for PF-07258669 in Older Adults

Pfizer Price Performance

Shares of PFE stock opened at $27.24 on Monday. The business’s fifty day moving average is $25.61 and its 200 day moving average is $25.10. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62. The stock has a market cap of $154.88 billion, a price-to-earnings ratio of 20.03 and a beta of 0.47. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $27.69.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. The firm had revenue of $17.56 billion for the quarter, compared to analysts’ expectations of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.25%. The company’s quarterly revenue was down 1.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.63 EPS. Research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be paid a $0.43 dividend. The ex-dividend date is Friday, January 23rd. This represents a $1.72 annualized dividend and a dividend yield of 6.3%. Pfizer’s dividend payout ratio is presently 126.47%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.